Last reviewed · How we verify
pulmonary surfactant — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
pulmonary surfactant (pulmonary surfactant) — National Heart, Lung, and Blood Institute (NHLBI). Replaces deficient or dysfunctional endogenous lung surfactant to reduce alveolar surface tension and prevent alveolar collapse during respiration.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| pulmonary surfactant TARGET | pulmonary surfactant | National Heart, Lung, and Blood Institute (NHLBI) | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- pulmonary surfactant CI watch — RSS
- pulmonary surfactant CI watch — Atom
- pulmonary surfactant CI watch — JSON
- pulmonary surfactant alone — RSS
Cite this brief
Drug Landscape (2026). pulmonary surfactant — Competitive Intelligence Brief. https://druglandscape.com/ci/pulmonary-surfactant. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing